Health News

VION PHARMACEUTICALS, INC. (OTC Bulletin Board: VION) announced that an analysis of clinical data of its lead anticancer agent Onrigin (laromustine) Injection in acute myeloid leukemia (AML) would be presented in a poster at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting in Orlando, Florida.

Read more

Filed under: Pharmacy News
Tags: leukemia, Oncology, Pharmacy

Related posts

• Vion Pharmaceuticals files SPA for Onrigin-LDAC combination Phase II/III trial (0)
  VION PHARMACEUTICALS, INC. announced today that it had filed a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA) related to a randomized Phase II/III trial of its oncology therapeutic Onrigin™ (laromustine) Injection in combination with low-dose Ara-C (LDAC) in elderly patients with newly diagnosed acute myeloid leukemia (AML). The primary [...]
  
  
• Vion Pharmaceuticals Announces Results Of The Oncologic Drugs Advisory Committee Meeting For Onrigin(TM) (0)
  VION PHARMACEUTICALS, INC. (OTC Bulletin Board: VION) announced the results of the Oncologic Drugs Advisory Committee (ODAC) Meeting at which data for its lead oncology therapeutic Onrigin(TM)(laromustine) Injection were presented for the indication of remission induction treatment for patients sixty years of age or older with de novo poor-risk acute myeloid leukemia (AML). [...]
  
  
• Vion Pharmaceuticals Announces Filing Of Special Protocol Assessment For Onrigin(TM) (0)
  VION PHARMACEUTICALS, INC. (OTC Bulletin Board: VION) announced that it had filed a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA) related to a randomized Phase II/III trial of its oncology therapeutic Onrigin™ (laromustine) Injection in combination with low-dose Ara-C (LDAC) in elderly patients with newly diagnosed acute myeloid leukemia (AML)... Read [...]
  
  
• Tosedostat and OPAXIO study results to be presented at ASCO Annual Meeting (0)
  Cell Therapeutics, Inc. announced that data from a study with OPAXIO, in patients with newly diagnosed high-grade gliomas, and interim results from a study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia, will be presented at the 2011 American Society of Clinical Oncology Annual Meeting, which will be held June 3-7, [...]
  
  
• St. Jude finds more than 100 gene variations linked with response to leukemia treatment (0)
  Scientists from St. Jude Children's Research Hospital and the Children's Oncology Group (COG) have discovered in children with acute lymphoblastic leukemia (ALL) scores of inherited genetic variations that clinicians might be able to use as guideposts for designing more effective chemotherapy for this cancer. Read more [tags] Pharmacy News [/tags]